Rituximab-induced remission of a gastric MALT lymphoma

Yvonne H. Datta, Bal Kampalath, David G. Binion

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Gastric MALT lymphoma is usually associated with H. pylori infection, and responds to treatment with antibiotics and a proton pump inhibitor. We report a case of H. pylori negative gastric MALT lymphoma. The patient was followed conservatively for 2 years until she developed gastrointestinal bleeding with significant anemia. She was treated with rituximab 375 mg/m2 weekly for four doses, which resulted in a biopsy proven complete remission. Rituximab therapy is a reasonable, well tolerated treatment alternative for MALT lymphomas not associated with H. pylori.

Original languageEnglish (US)
Pages (from-to)1297-1299
Number of pages3
JournalLeukemia and Lymphoma
Issue number6
StatePublished - Jun 2004


  • Gastric
  • Lymphoma
  • MALT
  • Rituximab


Dive into the research topics of 'Rituximab-induced remission of a gastric MALT lymphoma'. Together they form a unique fingerprint.

Cite this